Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity
1998

Improving Avidin for Cancer Treatment

Sample size: 7 publication Evidence: moderate

Author Information

Author(s): M Chinol, P Casalini, M Maggiolo, S Canevari, ES Omodeo, P Caliceti, FM Veronese, M Cremonesi, F Chiolerio, E Nardone, AG Siccardi, G Paganelli

Primary Institution: European Institute of Oncology

Hypothesis

Can biochemical modifications of avidin enhance its pharmacokinetics and reduce its immunogenicity for safer cancer therapy?

Conclusion

The study found that modifying avidin with polyethylene glycol (PEG) improved its blood clearance and reduced its immunogenicity.

Supporting Evidence

  • Modified avidin showed a longer plasma half-life compared to native avidin.
  • Immunogenicity was significantly reduced in PEGylated forms of avidin.
  • Biodistribution studies indicated lower liver and kidney uptake for PEGylated avidins.

Takeaway

Scientists changed avidin to make it work better in cancer treatments, helping it stay in the body longer and cause fewer allergic reactions.

Methodology

The study involved preparing modified forms of avidin and testing their behavior in mice after injection.

Limitations

The modifications affected biotin binding and the study was conducted in mice, which may not fully represent human responses.

Participant Demographics

6-week-old female Balb/c mice

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication